These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 26522274)

  • 21. Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S.
    Assadollahi V; Rashidieh B; Alasvand M; Abdolahi A; Lopez JA
    J Cell Biochem; 2019 Aug; 120(8):13046-13055. PubMed ID: 30916819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.
    Meador CB; Jin H; de Stanchina E; Nebhan CA; Pirazzoli V; Wang L; Lu P; Vuong H; Hutchinson KE; Jia P; Chen X; Eisenberg R; Ladanyi M; Politi K; Zhao Z; Lovly CM; Cross DA; Pao W
    Mol Cancer Ther; 2015 Feb; 14(2):542-52. PubMed ID: 25477325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype.
    Xu J; Zhao X; He D; Wang J; Li W; Liu Y; Ma L; Jiang M; Teng Y; Wang Z; Gu M; Wu J; Wang Y; Yue W; Zhang S
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1413-1422. PubMed ID: 29797219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
    Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites.
    Wittlinger F; Heppner DE; To C; Günther M; Shin BH; Rana JK; Schmoker AM; Beyett TS; Berger LM; Berger BT; Bauer N; Vasta JD; Corona CR; Robers MB; Knapp S; Jänne PA; Eck MJ; Laufer SA
    J Med Chem; 2022 Jan; 65(2):1370-1383. PubMed ID: 34668706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Noncovalent wild-type-sparing inhibitors of EGFR T790M.
    Lee HJ; Schaefer G; Heffron TP; Shao L; Ye X; Sideris S; Malek S; Chan E; Merchant M; La H; Ubhayakar S; Yauch RL; Pirazzoli V; Politi K; Settleman J
    Cancer Discov; 2013 Feb; 3(2):168-81. PubMed ID: 23229345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance
    Starrett JH; Guernet AA; Cuomo ME; Poels KE; van Alderwerelt van Rosenburgh IK; Nagelberg A; Farnsworth D; Price KS; Khan H; Ashtekar KD; Gaefele M; Ayeni D; Stewart TF; Kuhlmann A; Kaech SM; Unni AM; Homer R; Lockwood WW; Michor F; Goldberg SB; Lemmon MA; Smith PD; Cross DAE; Politi K
    Cancer Res; 2020 May; 80(10):2017-2030. PubMed ID: 32193290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
    Jänne PA; Yang JC; Kim DW; Planchard D; Ohe Y; Ramalingam SS; Ahn MJ; Kim SW; Su WC; Horn L; Haggstrom D; Felip E; Kim JH; Frewer P; Cantarini M; Brown KH; Dickinson PA; Ghiorghiu S; Ranson M
    N Engl J Med; 2015 Apr; 372(18):1689-99. PubMed ID: 25923549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer.
    Ricciuti B; Chiari R; Chiarini P; Crinò L; Maiettini D; Ludovini V; Metro G
    Clin Drug Investig; 2016 Aug; 36(8):683-6. PubMed ID: 27177916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
    Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
    Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
    Bean J; Brennan C; Shih JY; Riely G; Viale A; Wang L; Chitale D; Motoi N; Szoke J; Broderick S; Balak M; Chang WC; Yu CJ; Gazdar A; Pass H; Rusch V; Gerald W; Huang SF; Yang PC; Miller V; Ladanyi M; Yang CH; Pao W
    Proc Natl Acad Sci U S A; 2007 Dec; 104(52):20932-7. PubMed ID: 18093943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
    Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
    Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.
    Mizuuchi H; Suda K; Murakami I; Sakai K; Sato K; Kobayashi Y; Shimoji M; Chiba M; Sesumi Y; Tomizawa K; Takemoto T; Sekido Y; Nishio K; Mitsudomi T
    Cancer Sci; 2016 Apr; 107(4):461-8. PubMed ID: 26845230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
    Niederst MJ; Sequist LV; Poirier JT; Mermel CH; Lockerman EL; Garcia AR; Katayama R; Costa C; Ross KN; Moran T; Howe E; Fulton LE; Mulvey HE; Bernardo LA; Mohamoud F; Miyoshi N; VanderLaan PA; Costa DB; Jänne PA; Borger DR; Ramaswamy S; Shioda T; Iafrate AJ; Getz G; Rudin CM; Mino-Kenudson M; Engelman JA
    Nat Commun; 2015 Mar; 6():6377. PubMed ID: 25758528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
    Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural Basis of AZD9291 Selectivity for EGFR T790M.
    Yan XE; Ayaz P; Zhu SJ; Zhao P; Liang L; Zhang CH; Wu YC; Li JL; Choi HG; Huang X; Shan Y; Shaw DE; Yun CH
    J Med Chem; 2020 Aug; 63(15):8502-8511. PubMed ID: 32672461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
    Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
    Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
    Gazdar AF
    Oncogene; 2009 Aug; 28 Suppl 1(Suppl 1):S24-31. PubMed ID: 19680293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
    Ercan D; Xu C; Yanagita M; Monast CS; Pratilas CA; Montero J; Butaney M; Shimamura T; Sholl L; Ivanova EV; Tadi M; Rogers A; Repellin C; Capelletti M; Maertens O; Goetz EM; Letai A; Garraway LA; Lazzara MJ; Rosen N; Gray NS; Wong KK; Jänne PA
    Cancer Discov; 2012 Oct; 2(10):934-47. PubMed ID: 22961667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.